In certain aspects, the disclosure relates to a nucleic acid molecule encoding two or more different thanotransmission polypeptides. Thanotransmission is communication between cells that is a result of activation of a cell turnover pathway in a target cell, which signals a responding cell to undergo a biological response. Vectors (e.g., engineered viruses, plasmids and transposons), cells and pharmaceutical compositions comprising one or more nucleic acid molecules encoding two or more thanotransmision polypeptides are also disclosed. Methods of promoting thanotransmission by a target cell, methods of promoting an immune response in a subject, and methods of treating cancer in a subject are further disclosed.

The present disclosure generally relates to a T-cell epitope compounds and compositions effective against African Swine Fever Virus (“ASFV”) and related diseases. Such T-cell epitope compounds and compositions include immunogenic T-cell epitope polypeptides (including concatemeric polypeptides and chimeric or fusion polypeptides), as well as nucleic acids, plasmids, vectors, and cells which express the polypeptides, pharmaceutical compositions, and vaccines, and the uses thereof. The present disclosure is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against ASFV infection and related diseases.

The present disclosure generally relates to a T-cell epitope compounds and compositions effective against African Swine Fever Virus (“ASFV”) and related diseases. Such T-cell epitope compounds and compositions include immunogenic T-cell epitope polypeptides (including concatemeric polypeptides and chimeric or fusion polypeptides), as well as nucleic acids, plasmids, vectors, and cells which express the polypeptides, pharmaceutical compositions, and vaccines, and the uses thereof. The present disclosure is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against ASFV infection and related diseases.

The present disclosure provides a recombinant adenovirus for expressing African swine fever virus (ASFV) EP153R-EP402R protein and a construction method thereof, and belongs to the technical field of genetic engineering. In the present disclosure, a recombinant adenovirus vector pAD-CMV-EGFP-EP153R-EP402R is obtained through a series of intermediate processes using a recombinant adenovirus shuttle vector pENTRE-EGFP-TOPO; the recombinant adenovirus vector is linearized to transfect AD293 cells, a recombinant virus is screened according to cytopathy formed by adenovirus infection, an adenovirus packaging process is achieved, and the recombinant adenovirus for expressing ASFV EP153R-EP402R protein is obtained, laying a foundation for the construction of a recombinant adenovirus vaccine for expressing the ASFV EP153R-EP402R protein.

The present disclosure provides a recombinant adenovirus for expressing African swine fever virus (ASFV) EP153R-EP402R protein and a construction method thereof, and belongs to the technical field of genetic engineering. In the present disclosure, a recombinant adenovirus vector pAD-CMV-EGFP-EP153R-EP402R is obtained through a series of intermediate processes using a recombinant adenovirus shuttle vector pENTRE-EGFP-TOPO; the recombinant adenovirus vector is linearized to transfect AD293 cells, a recombinant virus is screened according to cytopathy formed by adenovirus infection, an adenovirus packaging process is achieved, and the recombinant adenovirus for expressing ASFV EP153R-EP402R protein is obtained, laying a foundation for the construction of a recombinant adenovirus vaccine for expressing the ASFV EP153R-EP402R protein.

A PCV2 vaccine and a method of vaccinating against PCV2 are provided herein. The PCV2 vaccine includes a PCV2 infectious clone with a re-engineered PCV2 capsid in the backbone thereof, wherein the re-engineered PCV2 capsid includes a modified immunogenic region. The method of vaccinating against PCV2 includes administering the PCV2 vaccine including a PCV2 infectious clone with a re-engineered PCV2 capsid in the backbone thereof to a subject in need thereof.

A PCV2 vaccine and a method of vaccinating against PCV2 are provided herein. The PCV2 vaccine includes a PCV2 infectious clone with a re-engineered PCV2 capsid in the backbone thereof, wherein the re-engineered PCV2 capsid includes a modified immunogenic region. The method of vaccinating against PCV2 includes administering the PCV2 vaccine including a PCV2 infectious clone with a re-engineered PCV2 capsid in the backbone thereof to a subject in need thereof.

The present invention relates to a complex of a protein comprising zinc oxide-binding peptides and zinc oxide nanoparticles, to the use thereof as a drug delivery carrier for manufacturing medicines, and to a vaccine composition and a contrast agent comprising the composite. The protein comprising zinc oxide-binding peptides significantly improves the in vivo availability of zinc oxide-binding peptides, and therefore the complex of the present invention can be used not only as a drug delivery carrier for in vivo drug delivery or intracellular drug delivery, but also for in vivo imaging or cell imaging. The complex can be used for producing separating agents for effectively separating biological materials, therapeutic agents for hyperthermia, etc., contrast agents for MRI, and beads applicable to biosensors.

The invention provides methods for enhancing the delivery of viral vectors to the eye of a subject by administering a proteasome inhibitor or and a viral vector ending a gene of interest to the eye.

The present invention provides a subunit vaccine composition for African swine fever, and a preparation therefor and use thereof, which fall within the technical field of animal vaccines and veterinary biological products. The vaccine comprises an exterior envelope protein CD2V derived from African swine fever virus and an exterior envelope capsid protein p72 derived from African swine fever virus and a pharmaceutically acceptable adjuvant. The method for preparing the vaccine comprises: 1) preparing the exterior envelope protein CD2V derived from African swine fever virus and the exterior envelope capsid protein p72 derived from African swine fever virus; 2) mixing the exterior envelope protein CD2V derived from African swine fever virus with the exterior envelope capsid protein p72 derived from African swine fever virus prepared in step 1), so as to prepare an antigen solution; and 3) emulsifying the antigen solution and ISA 201 VG at a volume ratio of 46:54.